HLA Class I or Class II and Disease Association: Catch the Difference If You Can.
作者信息
Fiorillo Maria Teresa, Paladini Fabiana, Tedeschi Valentina, Sorrentino Rosa
机构信息
Department of Biology and Biotechnology "Charles Darwin", Sapienza University of Rome, Rome, Italy.
出版信息
Front Immunol. 2017 Nov 7;8:1475. doi: 10.3389/fimmu.2017.01475. eCollection 2017.
Abstract
摘要
相似文献
1
HLA Class I or Class II and Disease Association: Catch the Difference If You Can.
Front Immunol. 2017 Nov 7;8:1475. doi: 10.3389/fimmu.2017.01475. eCollection 2017.
2
[Binding-peptide motifs of HLA class II molecules susceptible to autoimmune diseases].
Nihon Rinsho. 1997 Jun;55(6):1384-96.
3
Molecular and cellular analyses of HLA class II-associated susceptibility to autoimmune diseases in the Japanese population.
Mod Rheumatol. 2001 Jun;11(2):103-12. doi: 10.3109/s101650170020.
4
Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
Arthritis Res. 2000;2(1):75-84. doi: 10.1186/ar71.
5
Extraordinary cross-reactivity of an autoimmune T-cell receptor recognizing specific peptides both on autologous and on allogeneic HLA class II molecules.
Tissue Antigens. 2007 Jul;70(1):42-52. doi: 10.1111/j.1399-0039.2007.00849.x.
6
HLA class II transgenic mice mimic human inflammatory diseases.
Adv Immunol. 2008;97:65-147. doi: 10.1016/S0065-2776(08)00002-3.
7
Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex.
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6806-11. doi: 10.1073/pnas.111162298. Epub 2001 May 29.
8
Specificity, degeneracy, and molecular mimicry in antigen recognition by HLA-Class II restricted T cell receptors: implications for clinical medicine.
Mod Rheumatol. 2003 Sep;13(3):205-14. doi: 10.3109/s10165-003-0225-x.
9
HLA class II polymorphism: implications for genetic susceptibility to autoimmune disease.
Lab Invest. 1989 Jul;61(1):5-19.
10
Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Biol Blood Marrow Transplant. 2013 Jun;19(6):867-75. doi: 10.1016/j.bbmt.2013.03.003. Epub 2013 Mar 13.
引用本文的文献
1
Associations between HLA-II variation and antibody specificity are predicted by antigen properties.
Genome Med. 2025 Jun 2;17(1):65. doi: 10.1186/s13073-025-01486-w.
2
Evidence for Pathogen-Driven Selection Acting on in Response to Malaria in West Africa.
Ecol Evol. 2025 Feb 24;15(2):e70933. doi: 10.1002/ece3.70933. eCollection 2025 Feb.
3
MMPred: a tool to predict peptide mimicry events in MHC class II recognition.
Front Genet. 2024 Dec 10;15:1500684. doi: 10.3389/fgene.2024.1500684. eCollection 2024.
4
Evidence for immune activation in pathogenesis of the HLA class II associated disease, podoconiosis.
Nat Commun. 2024 Mar 6;15(1):2020. doi: 10.1038/s41467-024-46347-z.
5
Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity.
JAMA Netw Open. 2023 Oct 2;6(10):e2338612. doi: 10.1001/jamanetworkopen.2023.38612.
6
Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis.
RMD Open. 2023 Aug;9(3). doi: 10.1136/rmdopen-2023-003102.
7
Next-Generation Sequencing Technology: Current Trends and Advancements.
Biology (Basel). 2023 Jul 13;12(7):997. doi: 10.3390/biology12070997.
8
The genetic polymorphisms at the promoter region of gene, creating responsive elements for NF1/CTF and converting the TFII-D binding site to GR-alpha.
Mol Biol Res Commun. 2023;12(1):51-55. doi: 10.22099/mbrc.2023.46890.1813.
9
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.
Front Pharmacol. 2022 Feb 18;13:835136. doi: 10.3389/fphar.2022.835136. eCollection 2022.
10
Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?
Front Immunol. 2022 Jan 25;13:821598. doi: 10.3389/fimmu.2022.821598. eCollection 2022.
本文引用的文献
1
T cells from patients with Parkinson's disease recognize α-synuclein peptides.
Nature. 2017 Jun 29;546(7660):656-661. doi: 10.1038/nature22815. Epub 2017 Jun 21.
2
Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants.
Sci Transl Med. 2017 May 10;9(389). doi: 10.1126/scitranslmed.aai8708.
3
RNA editing signature during myeloid leukemia cell differentiation.
Leukemia. 2017 Dec;31(12):2824-2832. doi: 10.1038/leu.2017.134. Epub 2017 May 9.
4
An Unchartered Journey for Ribosomes: Circumnavigating Circular RNAs to Produce Proteins.
Mol Cell. 2017 Apr 6;66(1):1-2. doi: 10.1016/j.molcel.2017.03.011.
5
Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease.
Science. 2017 Apr 7;356(6333):44-50. doi: 10.1126/science.aah5298.
6
Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes.
Nat Med. 2017 Apr;23(4):501-507. doi: 10.1038/nm.4289. Epub 2017 Feb 27.
7
A large fraction of HLA class I ligands are proteasome-generated spliced peptides.
Science. 2016 Oct 21;354(6310):354-358. doi: 10.1126/science.aaf4384. Epub 2016 Oct 20.
8
Present Yourself! By MHC Class I and MHC Class II Molecules.
Trends Immunol. 2016 Nov;37(11):724-737. doi: 10.1016/j.it.2016.08.010. Epub 2016 Sep 7.
9
HLA-B51 Carriers are Susceptible to Ocular Symptoms of Behçet Disease and the Association between the Two Becomes Stronger towards the East along the Silk Road: A Literature Survey.
Ocul Immunol Inflamm. 2017 Feb;25(1):37-40. doi: 10.3109/09273948.2015.1136422. Epub 2016 Mar 8.
10
T(reg) stability: to be or not to be.
Curr Opin Immunol. 2016 Apr;39:39-43. doi: 10.1016/j.coi.2015.12.009. Epub 2016 Jan 15.
Zotero 插件